ArticleThe Journal of pharmacology and experimental therapeutics2025
Effects of methamphetamine-induced sleep disruption on intradimensional/extradimensional attentional set-shifting in adult rhesus monkeys.
Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cognitive performance has been shown to be negatively affected by both methamphetamine use and sleep disruption, independently. However, few studies have investigated the effects of methamphetamine-induced sleep disruptions on next-day executive functioning. The aim of the present study was to investigate the next-day cognitive effects of methamphetamine-induced sleep disruption on executive functioning in adult rhesus monkeys. Monkeys (4 males and 1 female) were fitted with primate collars to which actigraphy monitors were attached. Actigraphy-based sleep measures were assessed at night during baseline conditions and after methamphetamine administration (0.3 and 0.56 mg/kg, i.m.) 3 hours before "lights off." The monkeys then completed an intradimensional/extradimensional attentional set-shifting task (Cambridge Neuropsychological Test Automated Battery touchscreen system) the following day. Methamphetamine administration disrupted actigraphy-based sleep parameters, significantly decreasing sleep efficiency and increasing % wake, sleep latency, and sleep fragmentation at the highest dose tested (0.56 mg/kg) compared with baseline. Sleep impairment was associated with next-day cognitive deficits after treatment with methamphetamine at the dose of 0.56 mg/kg, with significantly increased total trials to completion, total errors, and total perseverative errors and decreased mean task accuracy compared with cognitive performance during baseline. Significant correlations were observed between actigraphy-based sleep measures and cognitive performance across all experimental conditions, with greater wake time and lower sleep efficiency being associated with worse cognitive performance. Our findings indicate that the sleep-disrupting effects of methamphetamine may play a role in this drug's cognition-disrupting effects. SIGNIFICANCE STATEMENT: The present study shows that methamphetamine-induced sleep disruption is associated with next-day impairments in cognitive measures in nonhuman primates. Addressing sleep disruptions may offer a novel treatment strategy to improving cognitive deficits associated with use of this stimulant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.